Fast generation of dendritic cells

Dendritic cells (DC) are potent antigen presenting cells capable of inducing immune responses. DC are widely used as vaccine adjuvant in experimental clinical settings. DC-based vaccines are normally generated using a standard 8 day DC protocol (SDDC). In attempts to shorten the vaccine production w...

Full description

Saved in:
Bibliographic Details
Published in:Cellular immunology 2009, Vol.260 (1), p.56-62
Main Authors: Kvistborg, P., Boegh, M., Pedersen, A.W., Claesson, M.H., Zocca, M.B.
Format: Article
Language:English
Subjects:
Antigens, CD - immunology
Antigens, CD - metabolism
Cell Culture Techniques - methods
Cell Differentiation - immunology
Coculture Techniques
Dendritic cells
Dendritic Cells - cytology
Dendritic Cells - immunology
Dendritic Cells - metabolism
Fast generation
Flow Cytometry
Humans
IL-10
IL-12
Lymphocyte Culture Test, Mixed
Phenotype
T-Lymphocytes - immunology
Time
Vaccines - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dendritic cells (DC) are potent antigen presenting cells capable of inducing immune responses. DC are widely used as vaccine adjuvant in experimental clinical settings. DC-based vaccines are normally generated using a standard 8 day DC protocol (SDDC). In attempts to shorten the vaccine production we have developed fast DC protocol by comparing two different fast DC protocols with SDDC. DC were evaluated by FACS analysis, and the optimal profile was considered: CD14 low, CD80 high, CD83 high, CD86 high, CCR7 high, HLA class I and II high. FACS profiles were used as the selection criteria together with yield and morphology. Two fast DC protocols fulfilled these criteria and were selected for functional analysis. Our results demonstrate that DC generated within 5 days or 48 h are comparable with SDDC both phenotypically and functionally. However, we found that 48 h DC were more susceptible than SDDC to the IL-10 inducing stimulus of TLR ligands (R848 and LPS). Thus to determine the clinical relevance of fast DC protocols in cancer settings, small phase I trials should be conducted monitoring regulatory T cells carefully.
ISSN:0008-8749
1090-2163
DOI:10.1016/j.cellimm.2009.09.003